



NDA 202231/S-003

**SUPPLEMENT APPROVAL**

Fresenius Kabi USA, LLC  
Attention: Aditi Dron  
Regulatory Affairs Manager  
1501 East Woodfield Road, Suite 300 East  
Schaumburg, IL 60173

Dear Ms. Dron:

Please refer to your Supplemental New Drug Application (sNDA) dated June 26, 2012, received June 26, 2012, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Levothyroxine Sodium for Injection, 100 mcg/vial, 200 mcg/vial (discontinued), and 500/mcg/vial.

This “Changes Being Effected” supplemental new drug application provides for the following changes in response to our supplement request letter dated March 29, 2012:

1. Deleted in the **HIGHLIGHTS** section, boxed warning,  
*“See full prescribing information for complete boxed warning.”*
2. Added directly under the heading **FULL PRESCRIBING INFORMATION: CONTENTS\***:  
**“WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS”**
3. Under the heading **FULL PRESCRIBING INFORMATION**, the boxed warning is added exactly as we asked that it appear in the **HIGHLIGHTS** section (i.e., without *“See full prescribing information for complete boxed warning.”*).
4. The **FULL PRESCRIBING INFORMATION** section, **DOSAGE AND ADMINISTRATION** subsection, **2.3 Reconstitution Directions**, is revised as follows:  
*“... Reconstituted drug product is preservative free and is stable for 4 hours. Use immediately after reconstitution. Discard any unused portion...”*

The following additional changes were made to the PI.

1. Deletion of the 200 mcg dosage strength effected changes to **DOSAGE AND ADMINISTRATION, DOSAGE FORMS AND STRENGTHS**, and **HOW SUPPLIED/STORAGE AND HANDLING** sections.
2. The revised part number and container closure statement were added to the **HOW SUPPLIED/STORAGE AND HANDLING** section (“This container closure is not made of natural rubber latex”).
3. The following sections were omitted as not being applicable: **DRUG ABUSE AND DEPENDENCE, REFERENCES**, and **PATIENT COUNSELING INFORMATION**.
4. Minor editorial changes (i.e., capitalization, punctuation, and spacing).

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text and with the minor editorial revision changing the version revision year to 12/2012 from 6/2011 in the labeling.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling text for the package insert, with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

We request that the labeling approved today be available on your website within 10 days of receipt of this letter.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Linda Galgay, Regulatory Project Manager, at (301) 796-5383.

Sincerely,

*{See appended electronic signature page}*

Mary H. Parks, MD  
Director  
Division of Metabolism and Endocrinology Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

ENCLOSURE(S):  
Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

MARY H PARKS  
12/20/2012